Shanghai Serum Bio-Technology Co. Ltd. A
Shanghai Serum Bio-Technology Co., Ltd. engages in the research, development, production, operation, and sales of antitoxin and antiserum products in China. It offers equine anti-tetanus immunoglobulin, anti-venin, and anti-rabies serum products. The company was founded in 1999 and is based in Shanghai, China.
Shanghai Serum Bio-Technology Co. Ltd. A (688163) - Net Assets
Latest net assets as of June 2025: CN¥1.11 Billion CNY
Based on the latest financial reports, Shanghai Serum Bio-Technology Co. Ltd. A (688163) has net assets worth CN¥1.11 Billion CNY as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.14 Billion) and total liabilities (CN¥28.69 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.11 Billion |
| % of Total Assets | 97.47% |
| Annual Growth Rate | 26.58% |
| 5-Year Change | 273.7% |
| 10-Year Change | N/A |
| Growth Volatility | 81.33 |
Shanghai Serum Bio-Technology Co. Ltd. A - Net Assets Trend (2019–2024)
This chart illustrates how Shanghai Serum Bio-Technology Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Shanghai Serum Bio-Technology Co. Ltd. A (2019–2024)
The table below shows the annual net assets of Shanghai Serum Bio-Technology Co. Ltd. A from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.10 Billion | +0.89% |
| 2023-12-31 | CN¥1.09 Billion | -3.19% |
| 2022-12-31 | CN¥1.12 Billion | +203.45% |
| 2021-12-31 | CN¥369.63 Million | +26.09% |
| 2020-12-31 | CN¥293.15 Million | -13.00% |
| 2019-12-31 | CN¥336.94 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Shanghai Serum Bio-Technology Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 52.3% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥57.52 Million | 5.25% |
| Other Components | CN¥1.04 Billion | 94.75% |
| Total Equity | CN¥1.10 Billion | 100.00% |
Shanghai Serum Bio-Technology Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Shanghai Serum Bio-Technology Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Nanjing Wondux Environmental Protection Technology Corp Ltd
SHG:688178
|
$144.06 Million |
|
Galectin Therapeutics Inc
NASDAQ:GALT
|
$144.10 Million |
|
Isabella Bank Corporation
OTCQX:ISBA
|
$144.13 Million |
|
Tracsis plc
PINK:TCIIF
|
$144.17 Million |
|
Aspo Oyj
HE:ASPO
|
$144.00 Million |
|
GULF MARINE SVCS LS -02
F:G0M
|
$143.98 Million |
|
Comstock Mining Inc
NYSE MKT:LODE
|
$143.98 Million |
|
A-LIVING SM.CI.SV. H YC 1
F:1V0
|
$143.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Shanghai Serum Bio-Technology Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,085,840,605 to 1,095,500,609, a change of 9,660,003 (0.9%).
- Net income of 44,290,403 contributed positively to equity growth.
- Dividend payments of 34,627,200 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥44.29 Million | +4.04% |
| Dividends Paid | CN¥34.63 Million | -3.16% |
| Other Changes | CN¥-3.20K | -0.0% |
| Total Change | CN¥- | 0.89% |
Book Value vs Market Value Analysis
This analysis compares Shanghai Serum Bio-Technology Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.37x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 5.79x to 2.37x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | CN¥4.15 | CN¥24.03 | x |
| 2020-12-31 | CN¥3.61 | CN¥24.03 | x |
| 2021-12-31 | CN¥4.55 | CN¥24.03 | x |
| 2022-12-31 | CN¥10.36 | CN¥24.03 | x |
| 2023-12-31 | CN¥10.03 | CN¥24.03 | x |
| 2024-12-31 | CN¥10.12 | CN¥24.03 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Shanghai Serum Bio-Technology Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.04%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.72%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 1.02x
- Recent ROE (4.04%) is below the historical average (12.52%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 19.52% | 34.96% | 0.52x | 1.08x | CN¥32.06 Million |
| 2020 | 21.55% | 34.04% | 0.57x | 1.11x | CN¥33.86 Million |
| 2021 | 20.69% | 36.65% | 0.52x | 1.09x | CN¥39.52 Million |
| 2022 | 5.72% | 36.85% | 0.15x | 1.04x | CN¥-47.96 Million |
| 2023 | 3.57% | 20.39% | 0.17x | 1.04x | CN¥-69.81 Million |
| 2024 | 4.04% | 22.72% | 0.17x | 1.02x | CN¥-65.26 Million |
Industry Comparison
This section compares Shanghai Serum Bio-Technology Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,043,310,248
- Average return on equity (ROE) among peers: 14.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Shanghai Serum Bio-Technology Co. Ltd. A (688163) | CN¥1.11 Billion | 19.52% | 0.03x | $144.05 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $124.02 Million | 4.50% | 1.13x | $80.66 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $525.49 Million | 14.76% | 1.41x | $1.02 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $174.34 Million | 36.11% | 1.61x | $288.51 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $642.80 Million | -4.58% | 0.44x | $244.62 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.69 Billion | 3.06% | 0.97x | $850.04 Million |
| Hualan Biological EngineeringInc (002007) | $1.86 Billion | 32.78% | 0.08x | $2.00 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $2.09 Billion | 4.42% | 0.71x | $784.18 Million |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $831.21 Million | 22.32% | 0.12x | $3.76 Billion |
| Baolingbao Biology Co Ltd (002286) | $2.04 Billion | 5.44% | 0.31x | $398.99 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $456.61 Million | 23.20% | 0.29x | $347.95 Million |